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Abstract
Background: Effective diagnosis of malaria is a major component of case management. Rapid diagnostic tests
(RDTs) based on Plasmodium falciparumhistidine-rich protein 2 (PfHRP2) are popular for diagnosis of this most
virulent malaria infection. However, concerns have been raised about the longevity of the PfHRP2 antigenaemia
following curative treatment in endemic regions.
Methods: A model of PfHRP2 production and decay was developed to mimic the kinetics of PfHRP2 antigenaemia
during infections. Data from two human infection studies was used to fit the model, and to investigate PfHRP2
kinetics. Four malaria RDTs were assessed in the laboratory to determine the minimum detectable concentration of
PfHRP2.
Results: Fitting of the PfHRP2 dynamics model indicated that in malaria naïve hosts, P. falciparum parasites of the
3D7 strain produce 1.4 × 10-13 g of PfHRP2 per parasite per replication cycle. The four RDTs had minimum
detection thresholds between 6.9 and 27.8 ng/mL. Combining these detection thresholds with the kinetics of
PfHRP2, it is predicted that as few as 8 parasites/μL may be required to maintain a positive RDT in a chronic
infection.
Conclusions: The results of the model indicate that good quality PfHRP2-based RDTs should be able to detect
parasites on the first day of symptoms, and that the persistence of the antigen will cause the tests to remain
positive for at least seven days after treatment. The duration of a positive test result following curative treatment is
dependent on the duration and density of parasitaemia prior to treatment and the presence and affinity of anti-
PfHRP2 antibodies.
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Background
Plasmodium falciparum causes the most severe form of
malaria, and contributes to high morbidity and mortality
in areas of the world where malaria is endemic. Accu-
rate diagnostics are paramount for efficient treatment of
falciparum malaria. In this context, the popularity of
malaria rapid diagnostic tests (RDTs) has increased due
to the WHO recommendation for parasitological confir-
mation of suspected malaria cases prior to treatment
[1]. Compared to microscopy, RDTs are easier to use,
do not require well-maintained microscopes and skilled
microscopists, and provide a timely result. The majority
of P. falciparum specific RDTs function by detecting a
water soluble protein produced by P. falciparum, namely
histidine-rich protein 2 (PfHRP2). Detection is accom-
plished using monoclonal antibodies specific for
PfHRP2. PfHRP2 is produced by the parasite throughout
its asexual lifecycle; it is expressed on the surface of
infected erythrocytes and released into the peripheral
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circulation during schizogony [2,3]. Due to the persis-
tence of the protein in the circulation, PfHRP2-detecting
RDTs have however been reported to have low specifi-
city for diagnosis of current malaria infection in areas of
high transmission [4] and following treatment [5,6]; that
is, the PfHRP2-detecting RDTs may return positive
results when parasites are not present in the blood. This
persistence also affects the suitability of PfHRP2-detect-
ing RDTs for diagnosis of malaria in endemic regions
where chronic asymptomatic infections are common. In
addition, the timing of onset of detectable antigenaemia
using the RDT, relative to the appearance of parasites in
the bloodstream at a level detectable by standard micro-
scopic examination of a thick blood film is not well
defined.
As mature P. falciparum parasites sequester in
splanchnic vascular beds during the last half of the asex-
ual life-cycle they are not accessible for microscopic
diagnosis at this time. An additional consequence of
sequestration is that the total parasite biomass may be
underestimated if peripheral blood sampling is relied
upon. It has, therefore, been proposed that quantitative
assays of PfHRP2 level provide a more accurate mea-
surement of parasite biomass and potentially assist in
determining the prognosis of severe malaria [2,7].
The kinetics of PfHRP2 antigenaemia are not well
understood, although key parameters such as rate of
production and elimination half-life have been estimated
from in vitro and in vivo studies [7,8]. In the current
study a model of the kinetics of PfHRP2 is developed
and used to assess its potential impact on the interpreta-
tion of malaria RDT results. This model was applied to
clinical data to estimate circulating PfHRP2 levels, as
well as the amount of PfHRP2 available for detection
using RDTs that include a red blood cell (RBC) lysis
step.
Methods
Modelling PfHRP2 kinetics
A mathematical model was developed to mimic the
kinetics of PfHRP2, incorporating both the production
and clearance of the protein during a P. falciparum
infection. In developing the model it was assumed that
the host was infected with a single, relatively synchro-
nous infection of P. falciparum with a two-day (48
hour) asexual life cycle.
Studies of in vitro culture of P. falciparum indicate
that PfHRP2 accumulates in the cell as the parasite
develops within the erythrocyte with little membrane
leakage, resulting in 78-99% of PfHRP2 being released
into the circulation when the erythrocyte ruptures dur-
ing schizogony [2]. The model assumed production of
PfHPR2 occurred early in the asexual cycle, with all the
protein remaining within the infected RBC (iRBC) until
the time of schizont rupture when it is instantaneously
released into the circulation. The number of parasites
replicating (i.e. schizonts rupturing) at a given time dur-
ing an infection was estimated from available clinical
data. Where required, parasite density was converted to
absolute number of parasites by multiplying the density
by an assumed blood volume of 5 L (5 × 106 μL).
Two scenarios for PfHRP2 distribution within the
body were considered; 1) the minimum circulating con-
centration, estimated assuming that PfHRP2 is water-
soluble and distributed in equilibrium throughout the
extracellular water volume of 14 L [9], 2) maximum cir-
culating concentration, estimated assuming PfHPR2 is
distributed only within the total blood volume of 5 L.
The elimination of PfHRP2 from the circulation was
assumed to be continuous following a first-order decay
process:
dk = exp
[
ln (0.5) k
3.67
]
= exp
[−0.18887k] (1)
where dk is the proportion of PfHRP2 remaining k
days after it was produced (k = 0,..., 25). The exponent
was based on the published PfHRP2 half-life of 3.67
days [7].
The absolute amount of PfHRP2 (in grams) for any
day during an infection (Ht) was calculated using equa-
tion (2), while the minimum (Hmint) and maximum
(Hmaxt) circulating concentrations of PfHRP2 (g/μL)
were calculated according to equations (3) and (4),
respectively.
Ht = f
t∑
j=1
dt−jpj (2)
where t is the time in days with t = 1 being the first
schizogony of the parasite, pj is the number of parasites
within the host replicating on day j, and f is the amount
of PfHRP2 produced per iRBC (g).
Hmint =
Ht
14× 106 (3)
Hmaxt =
Ht
5× 106 (4)
The concentration of PfHRP2 measured by RDT or
ELISA (Tmint and Tmaxt) exceeds Hmint and Hmaxt
since it contains the circulating PfHRP2 plus the
PfHRP2 within the iRBCs which is released due to cell
lysis as a consequence of an RDT or ELISA assay.
Tmint = Hmint +
f qt
5× 106 (5)
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Tmaxt = Hmaxt +
f qt
5× 106 (6)
where qt is the number of parasites within the host on
day t (qt = pt on replication days in a synchronous
infection).
Study datasets
To fit the model and assess sensitivity, the PfHRP2
kinetics model was applied to two datasets.
Study 1. The first dataset was from a prospective,
unblinded, Phase IIa clinical trial where volunteers were
infected with blood stage P. falciparum [10]. The sub-
jects were infected with approximately 1,800 P. falci-
parum (3D7 strain) asexual parasites, and were given
curative treatment soon after reaching the target parasi-
taemia of ≥ 1,000 parasites/mL, as determined by PCR
quantification [11]. Details of the study, including ethics
approval have been previously reported [10]. For the
current study data from subjects in the third study
cohort were considered, and of the nine subjects in this
cohort, three (subjects 12, 13 and 14) had sufficient
numbers of pre-treatment data points to calibrate the
model. Parasite density and corresponding PfHRP2 con-
centration were estimated from blood samples taken at
pre-specified time points (approximately once or twice
daily) from initial infection to parasite clearance.
To determine the concentration of circulating PfHRP2,
serial blood samples from each subject were assessed by
PfHRP2 ELISA (Malaria Ag. Pf. ELISA Standard Diag-
nostics Korea; product code 05EK50). To interpolate the
amount of PfHRP2 present in the blood samples, a cali-
bration curve was constructed using serial dilutions of a
3D7 P. falciparumculture supernatant and used as con-
trol standards in each ELISA. The concentration of
PfHRP2 in this culture supernatant had previously been
measured at 55.5 ng/mL by interpolating the ELISA
optical density of serial dilutions against a stock of
recombinant PfHRP2 protein with known concentration
(Lee, personal communication). PfHRP2 concentration
within each sample was determined by interpolating the
optical density of the sample with the standard curve
using the software package Softmax Pro (Molecular
Devices Inc.).
The pre-treatment parasitaemia data was used to fit
the f parameter in the maximum concentration model.
As the PfHRP2 quantification was conducted using RBC
pellets, rather than the serum, only the maximum con-
centration model was considered during the model fit-
ting. An initial value of f (f0) was assumed to be 5.2 ×
10-15 g, as this was the median value previously reported
for four P. falciparum isolates during in vitro culture
[8]. Calibration of the model to calculate the optimal
value for f (f*) was achieved by determining the
multiplication factor (m) which produced the minimum
residual sum of squares between the predicted PfHRP2
concentration and subject ELISA data such that f* =
f0m.
Study 2. The second dataset was a sample of three
patients with neurosyphilis who had been treated by
infection with P. falciparum [12]. Patients S561, S707
and S811 were selected as illustrative examples of a ‘nat-
ural infection’, as the malaria infection was not treated
with antimalarial drugs to modify the primary attack.
Patients S561 and S811 had no previous history of
malaria infection and were infected with the McLendon
strain of P. falciparum (blood-induced), whilst Patient
S707 was reinfected with the McLendon strain of P. fal-
ciparum after being infected with the same strain 30
days prior [13]. The parasitaemia data from this study
set was used to investigate the kinetics of PfHRP2 anti-
genaemia in symptomatic, untreated infections.
Threshold of detection of malaria RDTs
To assess the minimum PfHRP2 concentration detect-
able by malaria RDTs four different RDT products were
tested against serial dilutions of 3D7 parasite culture
supernatant containing a known concentration of
PfHRP2. This supernatant was the same used to gener-
ate the standard curve in the ELISA assay described for
Study 1 above. The products tested were Firstsign™ -
ParaView (Pan + Pf) Malaria Test (Catalogue # 2101
CB-25, Unimed International Inc), SD BIOLINE Malaria
Ag Pf/Pv (Catalogue # 05FK80, Standard Diagnostics
Inc), Carestart™ Malaria HRP2/pLDH (Pf/PAN)
COMBO (Catalogue # G0131, AccessBioInc) and ICT
Malaria Combo Cassette Test (Catalogue #ML02, ICT
Diagnostics).
Each sample with a specified concentration of PfHRP2
was added to the RDTs as per the manufacturer’s
instructions with the test scored as positive if the
PfHRP2 band was visible and negative if there was no
visible PfHRP2 band. The reader of the RDT was not
blinded to the concentration of PfHRP2 added to the
RDT. The maximum dilution producing a positive result
was classified as the RDT detection threshold, and the
concentration of PfHRP2 corresponding to this dilution
was calculated.
Results
Estimation of amount of PfHRP2 produced by parasites
The PfHRP2 model was calibrated using data from
Study 1. The optimal individualized multiplication factor
(m) for subjects varied between 17.5 and 39.4, suggest-
ing that the amount of PfHRP2 produced by the 3D7 P.
falciparum parasites was considerably higher than pre-
viously reported (Table 1). The mean multiplication fac-
tor for the three subjects was 27.1, resulting in an
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estimate of 1.4 × 10-13 g of PfHRP2 produced per para-
site per replication cycle. The fit of the predicted
PfHRP2 quantities for each individual using the mean
optimal multiplication factor is presented in Figure 1.
Kinetics of PfHRP2 in untreated infections
The model was used to investigate the kinetics of
PfHRP2 antigenaemia during an infection by using para-
sitaemia data from the three neurosyphilis patients
(S561, S707 and S811) in Study 2. The amount of circu-
lating PfHRP2 (Hmint and Hmaxt), as well as the
amount of PfHRP2 predicted to be measurable by
ELISA (Tmint and Tmaxt) were calculated (Figure 2).
The duration and first day that PfHRP2 could be
detected at concentrations between 10 ng/mL and 100
ng/mL were estimated for each patient. Due to the
potential for different P. falciparum parasite strains to
produce different quantities of PfHRP2 (f), the model
was applied using the optimal value determined in
Study 1 (fitted model, f = 1.4 × 10-13 g) as well as the
previously reported value of 5.2 × 10-15 g [8] (unad-
justed model) (Table 2). Considering a threshold of 100
ng/mL, the first day that PfHRP2 was predicted to be
detectable was Day 2 for all three patients under the
fitted model, and Day 4 or Day 7 under the unadjusted
model for patients S561 and S811, and S707, respec-
tively. For the fitted model, the number of days that
PfHRP2 was predicted to be greater than 100 ng/mL
ranged between 25 and 50 days under the minimum cir-
culation model and between 29 and 56 days under the
maximum circulation model. The duration during an
infection when the PfHRP2 antigenaemia was above the
nominated thresholds was always longer for the maxi-
mum circulation model compared to the minimum cir-
culation model, and the model output was highly
sensitive to changes in f. The fitted model always pro-
duced a longer period of antigenaemia above a thresh-
old, and an equal or earlier transition to this state, than
the unadjusted model, due to the higher production of
PfHRP2 per parasite per replication cycle.
The parasitaemia time-course from subjects in Study 1
was used to assess the longevity of circulating PfHRP2
following curative treatment. In these three subjects the
amount of PfHRP2 decayed to be less than 110 ng/L 12
Table 1 Optimal multiplication factor for production of PfHRP2 by 3D7 P.falciparum parasites
Subject Treatment day No. pre-treatment data points Optimal multiplication factor (m) Estimated PfHRP2 produced/parasite (f*)
12 7.5 4 24.4 127 fg
13 7.5 3 17.5 91 fg
14 9.5 6 39.4 205 fg
The estimated quantity of PfHRP2 produced per parasite is calculated as m x 5.2 fg.
Figure 1 Parasitaemia and ELISA data from Study 1, along with
the predictedPfHRP2 concentration. Data are presented for a)
Patient 12, b) Patient 13 and c) Patient 14. The PfHRP2
concentrations were predicted by applying the fitted model with
the mean optimal PfHRP2 production of 1.4 × 10-13 g per parasite
per replication cycle.
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days, 7 days and 8 days after curative treatment for sub-
jects 12, 13 and 14, respectively.
Chronic infections - the minimum number of parasites
required to maintain PfHRP2 above a threshold
The equilibrium parasite density required to maintain
the PfHRP2 level above a nominated threshold was also
determined for both the minimum and maximum circu-
lation models (Figure 3). Applying these parasite
densities resulted in the concentration of PfHRP2 gradu-
ally increasing until approximately Day 20, after which it
plateaus at the equilibrium value. Linear regression
models were fitted to determine the relationship
between the threshold concentration (ng/μL) and equili-
brium parasite density (parasites/μL). Statistically signifi-
cant models were achieved (P < 0.001) and are reported
below. The values in brackets represent the SE of the
coefficients.
Equilbrium no. of parasites (minimum model) = 0.7 + 2311.9× PfHRP2 threshold
(0.1) (2.3)
Equilbrium no. of parasites (minimum model) = 0.6 + 1044.3× PfHRP2 threshold
(0.1) (3.4)
These estimates of the equilibrium number of para-
sites represent the minimum number of parasites
required consistently over time to maintain the level of
PfHRP2 above a nominated threshold. Parasite densities
above the equilibrium would always produce PfHRP2
levels over the threshold. Fluctuating parasite densities,
as may be seen in chronic infections, will also maintain
PfHRP2 levels above the threshold provided the period
of parasitaemia below the equilibrium value is short; the
maximum duration of low parasitaemia will be depen-
dent on the parasite dynamics and amount of PfHRP2
produced immediately prior to the drop in parasite
density.
Malaria RDT detection thresholds
The performances of each RDT against known PfHRP2
concentrations are shown in Table 3. The lowest dilu-
tions at which positive test results occurred were 27.75
ng/mL, 6.94 ng/mL and 6.94 ng/mL for the Firstsign™ -
ParaView (Pan + Pf) Malaria Test, SD BIOLINE Malaria
Ag Pf/Pv, and Carestart™ Malaria HRP2/pLDH (Pf/
PAN) COMBO (Catalogue # G0131, AccessBioInc),
respectively. The ICT Malaria Combo Cassette Test pro-
duced a faint positive band when tested against the
negative control (culture media) and the lowest PfHRP2
dilutions (Table 3). The band intensity for this product
increased when tested with a sample containing 13.88
ng/mL of PfHRP2, so this concentration was considered
to be the minimum level of detection for this product.
Applying these detection thresholds to the estimated
equilibrium equations above indicates that the threshold
parasitaemia that would be required to maintain a posi-
tive RDT in a chronic infection would be between 8 and
65 parasites/μL, dependent on the distribution of PfHRP2
within the body and the specific product (Table 4).
Discussion
Understanding the kinetics of PfHRP2 is important to
understanding the performance characteristics of
Figure 2 Parasitaemia and estimatedPfHRP2 concentrations
over the course of untreated infections. Data are presented for
patients a) S561, b) S707 and c) S811 in Study 2. Predicted PfHRP2
concentrations are for the maximum (Hmax) and minimum (Hmin)
circulating PfHRP2, and the PfHRP2 concentration which would be
measured during and ELISA or RDT (Tmax and Tmin) which includes
intracellular PfHRP2 which is released during the assay.
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malaria RDTs that detect this antigen. For optimal clini-
cal diagnosis RDTs need to return a positive result at
the time of first fever in malaria naïve individuals. In
contrast, the slow decay of the antigen has implications
for the utility of PfHRP2-based RDTs in endemic coun-
tries where low level infections are prevalent, and for
the detection of recrudescent infections following treat-
ment [5,6].
A key parameter in modelling the kinetics of PfHRP2
antigenaemia is the amount of PfHRP2 produced by one
parasite during one replication cycle (f). It has been
previously reported that each P. falciparum parasite pro-
duces 5.2 fg (range, 1.1 - 13.0 fg) of PfHRP2 per cycle
[8]. However, when this production level was used in
the model, the concentration of PfHRP2 was predicted
to be considerably lower than that actually measured in
malaria naïve individuals infected with blood-stage 3D7
P. falciparum parasites. This difference may be a conse-
quence of the differences between testing antigen pro-
duction from cultures grown in vitro compared to in
vivo measurements, a consequence of measurement
error and stochastic variability, or the result of natural
variation in protein production between different para-
site strains [14]. The subjects in Study 1 were all
infected by the same 3D7 parasite stain so genetic varia-
bility in the production of PfHRP2 should be minimal.
Therefore, the two-fold variation between the calculated
optimal values for the amount of PfHRP2 produced per
parasite per replication cycle is likely a result of mea-
surement error in the low parasite densities or ELISA
assay, or stochastic variability in PfHRP2 production by
individual parasites, possibly in response to host factors.
The model developed was applied under two assump-
tions: 1) a minimum concentration model in which the
PfHRP2 was assumed to be distributed throughout the
extracellular water of the host and 2) a maximum con-
centration model in which the PfHRP2 was assumed to
be restricted to the bloodstream only. It is highly likely
that the actual distribution of PfHRP2 is somewhere
between these two extremes so the values presented
should be viewed in this context. For simplicity, it was
assumed in the model that PfHRP2 was produced early
in the asexual life cycle, although in vitro data indicate
that PfHRP2 accumulates throughout the cycle [2]. This
assumption will not impact the calculations for the
Table 2 Characteristics of predicted PfHRP2 kinetics in illustrative untreated infections
Patient Day of
first fever
PfHRP2
threshold (ng/
mL)
Fitted model Unadjusted model
First day above threshold
(MinCM, MaxCM)
Days above
threshold (range)
First day above threshold
(MinCM, MaxCM)
Days above
threshold (range)
S561 2 100 2,2 32-34 4,3 9-15
20 2,2 39-46 2,2 19-25
10 2,2 44-51 2,2 24-31
S707 4 100 2,2 25-29 7,5 2-6
20 2,2 31-35 5,5 10-15
10 2,1 34-40 5,3 13-25
S811 2 100 2,2 50-56 4,4 2-7
20 2,2 59-64 4,2 21-31
10 2,2 63-68 2,2 29-47
The kinetics are summarized by the day they first exceed a nominated threshold under the minimum (MinCM) and maximum circulating PfHRP2 models (MaxCM)
and the total number of days they are above this threshold. A range for the number of days above the threshold is given by combining the results from the
MinCM and MaxCM models. Results are presented using the mean PfHRP2 production fitted in this study (fitted model) and also the previously reported PfHRP2
production of 5.2 fg/parasite/replication cycle (unadjusted model) [8].
Figure 3 Predicted minimum number ofP. falciparumparasites
required to maintainPfHRP2 concentration above a specified
threshold. Data are presented for the fitted maximum circulating
model (Tmax, red) and minimum circulating model (Tmin, blue).
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amount of circulating antigen, but may produce a slight
overestimation of the amount of antigen measurable by
RDT or ELISA. The magnitude of the overestimation
will depend on the relative amount of antigen contained
within the cells at the time of the assay compared to the
amount of circulating antigen, factors dependent on the
parasite density and duration of the infection prior to
sampling.
It was recently reported that a commercial PfHRP2
ELISA kit could detect PfHRP2 concentrations down to
110 ng/L [15]. In the current study where four commer-
cial RDTs were tested against the same PfHRP2 antigen,
the diagnostic sensitivity of the tests varied between 6.9
μg/L and 27.7 μg/L of PfHRP2. The model output
shows that for the fitted model, these values are
achieved on, or immediately prior, to the first day of
fever for the three patients in Study 2. In Study 1, the
predicted amount of PfHRP2 would have been insuffi-
cient to produce a positive RDT test, as subjects were
treated before becoming symptomatic, with peak para-
site densities less than 10 parasites/μL. Field data indi-
cates that PfHRP2-detecting RDTs can detect parasite
densities less than 100 parasites/μL [16,17]. The model
predictions indicate that the malaria RDTs tested here
would be able to diagnose an infection at the time of
first fever. A lower level of PfHRP2 production as in the
unadjusted model, or higher detection thresholds in the
RDT may cause a delay in a positive RDT result.
The model informs understanding on how duration of
infection and parasite density impact on the longevity of
PfHRP2 in natural infections. This replicates field data,
where children with higher parasite densities at the time
of treatment had a significantly longer antigen persis-
tence compared to children with lower parasite densities
[18]. In Study 1, subjects were treated prior to becoming
symptomatic, and the peak parasitaemia was much
lower than would occur in a natural infection. Thus, the
longevity of PfHRP2 in this circumstance is a likely
underestimate of the expected duration of a detectable
antigenaemia in symptomatic infection. Indeed, as few
as eight parasites/μL may be required to maintain
PfHRP2 equilibrium above 6.9 μg/L using the parameter
space described.
As has been reported before, the diagnostic sensitivity
of malaria RDTs targeting PfHRP2 is varied. The four
products examined here have also been assessed as part
of the WHO Malaria Rapid Diagnostic Test Programme
where they were tested against wild-type isolates [19,20].
Each product performed well when tested against 200 P.
falciparum parasites/μL, with overall positivity rates
varying from 93.0% for Firstsign™ - ParaView (Pan +
Pf) Malaria Test to 99.1% for Carestart™ Malaria
HRP2/pLDH (Pf/PAN) COMBO. The results from this
study are generally aligned with the product testing
results, as the product with the lowest panel detection
score, Firstsign™ - ParaView (Pan + Pf) Malaria Test,
had the highest PfHRP2 detection threshold. The mod-
elling results indicate that these tests should continue to
perform consistently well at concentrations in the order
of 50-100 parasites/μL, or better in some cases. This
result reflects a previous study in which the ICT Malaria
Combo Cassette Test was able to detect P. falciparum
Table 3 Malaria RDT reactivity againstP.falciparumculture supernatant
Product Intensity of PfHRP2 band
27.75 ng/
mL
13.88 ng/
mL
6.94 ng/
mL
3.47 ng/
mL
1.73 ng/
mL
0.87 ng/
mL
0 ng/mL (-ve
control)
Firstsign™ - ParaView (Pan + Pf) Malaria
Test
1 Neg Neg Neg Neg Neg Neg
SD BIOLINE Malaria Ag Pf/Pv 4 2 1 Neg Neg Neg Neg
Carestart™ Malaria HRP2/pLDH 1 1 1 Neg Neg Neg Neg
ICT Malaria Combo Cassette Test 4 2 1 1 1 1 1
Table entries are the intensities of the PfHRP2 band, scored from 1 (faint band) to 4 (strong band). Neg indicates no PfHRP2 band was visible.
Table 4 Predicted equilibrium parasite densities required to maintain a positive RDT test
Product Min. detectable PfHRP2 conc.
(ng/mL)
Est. no. parasites for MinCM
(parasites/μL)
Est. no. parasites for MaxCM
(parasites/μL)
Firstsign™ - ParaView (Pan + Pf)
Malaria Test
27.75 64.9 29.6
SD BIOLINE Malaria Ag Pf/Pv 6.94 16.7 7.8
Carestart™ Malaria HRP2/pLDH 6.94 16.7 7.8
ICT Malaria Combo Cassette Test 13.88* 32.8 15.1
* The lowest dilution which gives a band intensity > 1 to adjust for false positive result on negative control.
MinCM and MaxCM represent the minimum circulating model and maximum circulating model, respectively.
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parasites below 100/μL in field samples [17]. However it
is important to note that the four products tested in the
current study were within the top 40% of RDTs tested
by the WHO programme, as ranked by their perfor-
mance against wild-type P. falciparum isolates at 200
parasites/μL [21], and in addition were stored in ideal
conditions. Therefore, extrapolation of the results
obtained here to other RDTs is not recommended, par-
ticularly those products not achieving the same level of
performance as the tested sub-set.
The model and results presented in the current study
assume all PfHRP2 antigen produced by parasites in nat-
ural human infection is available for measurement.
However, it is possible that PfHRP2 binds or complexes
with other ligands or proteins such as PfHRP2-specific
antibodies, thereby reducing the amount available as
free circulating antigen. In this respect, it is known that
anti-PfHRP2 antibodies develop and may thereby act to
reduce the amount of free PfHRP2 circulating [3]. While
these factors have not been considered in the current
model, it is likely their effect would primarily influence
the longevity of the antigen in the circulation after treat-
ment. As RDTs cause RBC lysis, while there is an active
infection and parasites within the host, a blood sample
tested using an RDT would be able to detect the
PfHRP2 contained within the iRBCs provided that the
quantity of antibody in the serum is insufficient to bind
all of the PfHRP2 released from the iRBCs before it
reacts with the test band in the RDT. A caveat to this is
that the parasites must be present in the blood sample
tested by the RDT. Parasite sequestration can affect the
availability of parasites in finger-prick samples, a factor
which has not been considered in this model.
Conclusion
Malaria RDTs are becoming the cornerstone of effective
malaria diagnosis in primary healthcare settings. Under-
standing the benefits and limitations of these tools is
important to guide clinicians and product development.
The outputs of the mathematical model reported here
indicate that the PfHRP2-based RDTs that were tested
should be able to detect parasites on the first day of
symptoms, and that the persistence of the antigen will
cause the tests to remain positive for at least seven days
post-treatment. The post-treatment duration of positive
tests is dependent on the duration and density of parasi-
taemia prior to treatment, and possibility other factors
such as anti-PfHRP2 antibodies. In chronic infections a
steady state parasitaemia of only 4-65 parasites/μL is
likely to be sufficient to maintain a positive RDT result.
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